Ignite Creation Date:
2024-05-06 @ 5:47 PM
Last Modification Date:
2024-10-26 @ 2:35 PM
Study NCT ID:
NCT05424627
Status:
NOT_YET_RECRUITING
Last Update Posted:
2022-06-21
First Post:
2022-06-15
Brief Title:
Myeloid Derived Suppressor Cells in Systemic Lupus Erythematosus
Sponsor:
Central Hospital Nancy France
Organization:
Central Hospital Nancy France
Study Overview
Official Title:
Involvement of Myeloid Derived Suppressor Cells in Systemic Lupus Erythematosus
Status:
NOT_YET_RECRUITING
Status Verified Date:
2022-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MDSC-SLE
Brief Summary:
Systemic Lupus Erythematosus SLE is a chronic invalidating chronic condition with potential articular cutaneous renal and neurologic involvement Its pathophysiology is complex and involves genetic environmental and hormonal factors leading to tolerance rupture Among regulatory cells Myeloid Derived Suppressor Cells MDSCs have been described as being increased during SLE furthermore during flares MDSCs are defined phenotypically as being HLA-DR-CD3-CD19-CD33CD11b and either CD14 Monocytic MDSCs CD15 Granulocytic MDSCs or CD14-CD15- Early-stage MDSCs However data regarding their immunosuppressive properties are conflicting some studies identifying regulatory properties while other have demonstrated a pro-inflammatory involvement through the induction of Th17 lymphocytes
The objectives of this study is to assess the involvement of MDSC in SLE through accurate phenotypical and functional assessment as well as characterizing their immunometabolic profile and to identify innovative therapeutic strategies
The objectives of this study is to assess the involvement of MDSC in SLE through accurate phenotypical and functional assessment as well as characterizing their immunometabolic profile and to identify innovative therapeutic strategies
Detailed Description:
Systemic Lupus Erythematosus SLE is a chronic invalidating chronic condition with potential articular cutaneous renal and neurologic involvement Its pathophysiology is complex and involves genetic environmental and hormonal factors leading to tolerance rupture Among regulatory cells Myeloid Derived Suppressor Cells MDSCs have been described as being increased during SLE furthermore during flares MDSCs are defined phenotypically as being HLA-DR-CD3-CD19-CD33CD11b and either CD14 Monocytic MDSCs CD15 Granulocytic MDSCs or CD14-CD15- Early-stage MDSCs However data regarding their immunosuppressive properties are conflicting some studies identifying regulatory properties while other have demonstrated a pro-inflammatory involvement through the induction of Th17 lymphocytes
To gain insight into the involvement of MDSC in SLE both deep phenotypical characterization of MDSC and functional assessment will be performed as well as immunometabolic characterization This data will be correlated to the clinical presentation and activity of SLE
To gain insight into the involvement of MDSC in SLE both deep phenotypical characterization of MDSC and functional assessment will be performed as well as immunometabolic characterization This data will be correlated to the clinical presentation and activity of SLE
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None